Pembrolizumab Efficacy in Cancer Treatment
Urothelial Carcinoma: Category 1 Evidence
- The National Comprehensive Cancer Network recommends pembrolizumab as preferred second-line therapy and as first-line for cisplatin-ineligible patients with PD-L1 combined positive score ≥10 4
- Pembrolizumab demonstrates superior median overall survival of 10.3 months compared to 7.4 months with chemotherapy in the phase III KEYNOTE-045 trial, with significantly fewer grade 3-5 adverse events (15.0% vs 49.4%) 1, 2, 3
- In the KEYNOTE-052 trial, pembrolizumab achieved an overall response rate of 29% with 7% complete responses for first-line treatment in cisplatin-ineligible patients 1, 2
Cervical Cancer: Significant Survival Improvement
- Adding pembrolizumab to chemotherapy with or without bevacizumab significantly improved outcomes in persistent, recurrent, or metastatic cervical cancer, with median progression-free survival of 10.4 months versus 8.2 months with placebo (HR 0.62, p<0.001) 1, 2
Biomarker-Directed Indications
- Pembrolizumab received FDA approval for MSI-H or dMMR solid tumors regardless of tumor type, with an overall response rate of 39.6% and 78% of responders maintaining response for ≥6 months 6, 3
- In pancreatic cancer, pembrolizumab showed an objective response rate of 62% in 6 patients with dMMR tumors (2 complete responses, 3 progressive disease) 7
- The KEYNOTE-158 study of noncolorectal MSI-H/dMMR tumors reported an overall response rate of 34.3%, with median progression-free survival of 4.1 months and median overall survival of 23.5 months 7, 8
Vulvar Cancer: Limited but Promising Data
- In the KEYNOTE-158 trial, pembrolizumab achieved an overall response rate of 10.9% overall, with median progression-free survival of 2.1 months and median overall survival of 6.2 months 9, 8
Safety Profile
- Pembrolizumab demonstrates a favorable safety profile compared to chemotherapy, with grade 3-4 treatment-related adverse events occurring in 9-18% of patients across studies 1, 2, 10
- Immune-related adverse events include pneumonitis, colitis, hepatitis, endocrinopathies, and skin reactions 10
Duration of Response
- The median duration of response was 20.9 months in the KEYNOTE-045 trial for urothelial carcinoma 1